2/10 · Low — revenue is roughly flat through 2029E, no acceleration; a mature category and a shrinking (divesting) footprint
Technicals
Uptrend but stretched — $83.83 at the 52-wk high, above 50/200-DMA, RSI 69 (near overbought), +11.6% 12-mo (SPY +20.6%)
Conviction
Low — 0 expert voices, 0 claims in the Synthos KB; call rests entirely on the numbers
Position sizing
Watch-list; if owned, a small ~1–2% value/turnaround sleeve, not a core holding
Next catalyst
2026-08-04 Q2'26 earnings (Street EPS $1.13, revenue ~$2.68B); Food Ingredients sale process
Single biggest risk
The turnaround stalls — organic growth stays ~2% while ~$6B net debt and a history of impairments cap the re-rating
One-line thesis. IFF is a post-merger deleveraging story: a mature, defensive flavors/fragrances/enzymes business that over-levered on the 2021 DuPont N&B deal, took ~$5B+ of impairments since, and is now selling assets (Food Ingredients) to fix the balance sheet — the stock has already re-rated to roughly fair value, so there is neither a bargain nor a growth engine to justify chasing it here.
◆ Synthos call — AvoidIFF's problem is the business, not the price — weak growth and/or a deteriorating trajectory; a cheaper quote alone won't change our mind.
Downside Risk (lower = safer)
6/10 · High
Deleveraging (net-debt/EBITDA 2.6×) & multi-year impairment history, but beta ~1.0 and a real turnaround underway.
Growth Quality
3/10 · Low
~2-3% organic sales, low-single-digit EPS CAGR, sub-4% ROIC — a slow specialty compounder, not a grower.
Exponential Potential
2/10 · Low
No acceleration, flat revenue to 2029, mature $10B category — this is a restructuring story, not an exponential.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 9%/yrTo justify today’s $84, earnings would have to compound roughly 9% a year for 10 years (9% discount rate). Analysts forecast ~-0%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
IFF makes the smells and tastes inside everyday products — the flavor in your soda and yogurt, the scent in your shampoo and detergent, plus enzymes and cultures used in food. It is a solid, boring, defensive business: people keep buying flavored, scented products in good times and bad.
The problem is what happened behind the scenes. In 2021 IFF did a giant merger (buying DuPont's Nutrition & Biosciences unit) that loaded it with debt and goodwill. Since then it has written off billions when those assets turned out to be worth less than paid, and now management is selling off pieces (the Food Ingredients division) to pay down debt. The stock crashed, and over the last year it has climbed back — so today it trades at about what it's worth. Not cheap, not a screaming short.
Our verdict is Watch: a fairly-priced turnaround with no big upside and no expert conviction behind it. Here is what the three scores mean in plain terms:
Downside Risk 6/10 (a bit above average). Still carries meaningful debt and has a track record of nasty write-offs; the stock moves about as much as the market.
Growth Quality 3/10 (weak). Sales are barely growing — low single digits — and the company doesn't earn high returns on the money it invests.
Exponential Potential 2/10 (very low). Revenue is basically flat for years ahead. This is a repair job, not a rocket.
The one big worry: if the turnaround stalls — growth stuck near 2% while debt stays high — there is no cushion, because the easy recovery bounce has already happened.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLB (sector)), set to 100 a year ago
Solid = IFF · dashed = S&P 500 · dotted = XLB (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$83.83
Market cap$21B
P/E trailing4×
P/E FY26E / FY27E19× / 18×
EV / Sales2.5×
EV / EBITDA13.4×
Gross margin36.3%
Net margin7.9%
Dividend yield1.91%
Beta0.956
52-wk range$60 – $84
RSI(14)69
50 / 200-DMA$75 / $70
12-mo return+12% (SPY +21%)
Street target$88 ($75–$95)
Analyst grades24 Buy · 8 Hold · 1 Sell
FMP ratingB
Next earnings2026-08-05
What the experts actually said 0 traceable claims on IFF · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
International Flavors & Fragrances (NYSE: IFF) is a ~190-year-old (founded 1833) global specialty ingredients company. It sells the flavor compounds, fragrance compounds, enzymes, cultures, probiotics and food ingredients that go into other companies' consumer products — beverages, dairy, snacks, perfumes, personal care, detergents, and pharma excipients. It is a classic defensive, non-cyclical business (people consume flavored/scented goods regardless of the economy), but a low-growth one. Fiscal year ends December 31. CEO Erik Fyrwald (ex-Syngenta) is running an operational turnaround.
The overhang on the whole story is the 2021 DuPont Nutrition & Biosciences (N&B) merger — a transformational deal that roughly doubled revenue (2020 sales $5.1B → 2021 $11.7B) but loaded the balance sheet with debt and goodwill. Since then IFF has reported large GAAP losses driven by goodwill/intangible impairments (2022 net −$1.87B, 2023 net −$2.57B, 2025 net −$361M) as it marked those assets down. The current chapter is portfolio simplification and deleveraging: IFF is running a sale process for its Food Ingredients division (Q1'26 release) to raise cash and cut debt.
Revenue mix (FY2025, from filings — segments were reorganized in 2025):
By segment: Food Ingredients $3.28B · Taste $2.48B · Scent $2.48B · Health & Biosciences $2.28B · Pharma Solutions $0.37B. (Note the 2025 realignment split the old "Nourish" into Taste + Food Ingredients; Food Ingredients is the unit being sold, so the go-forward company is smaller and more focused on Taste/Scent/H&B.)
By geography: EMEA $3.73B (34%) · North America $3.20B · United States $3.08B (broken out within N. America reporting) · Asia $2.55B · Latin America $1.42B. A genuinely global, diversified base with no single-country dependence — a structural strength.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of IFF in the Synthos knowledge base. total_claims = 0; net-bullish voices = 0. No independent expert (bullish or bearish) in our panel has a traceable, dated claim on this name.
That means this note carries zero conviction weighting from the KB — the entire verdict is fundamentals- and quant-driven, built from the FMP financials, analyst estimates, management's own guidance (§9, half-weighted), and Synthos's scoring framework. We say this plainly rather than manufacture a thesis: honesty is the product, and where we have no edge from expert breadth, we do not pretend to. Readers should weight this note accordingly — it is a numbers-and-structure read, not a call backed by a chorus of high-skill voices.
(For context, the Street is constructive — 24 Buy / 8 Hold / 1 Sell, consensus target $88.38 — but sell-side ratings are not part of the Synthos conviction panel and are shown as context, not anchor.)
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
6 · Moderate-High
Net-debt/EBITDA 2.6× (management cites 2.5× credit-adj) is still elevated; a multi-year record of billion-dollar impairments; beta ~1.0. Offsets: defensive demand, deleveraging underway, dividend covered.
Growth Quality
3 · Weak
~2–3% comparable currency-neutral organic sales, low-single-digit forward EPS CAGR, ROIC ~3.6% (below cost of capital), ROE ~6%. A slow, capital-heavy compounder — not a quality grower.
Exponential Potential
2 · Low
Revenue is roughly flat FY25→FY29E ($10.9B → $12.0B, and shrinking near-term as it divests). No acceleration, mature category, footprint getting smaller. This is a restructuring, not an exponential.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, and the cases bound the range.
Case
Key assumptions
Fair value
Bull
Turnaround executes: comparable growth holds ~4%, Food Ingredients sold at a good price and proceeds cut net debt toward ~1.5×, margins expand. FY27E EPS-ex-amort ~$5.00 earns a re-rated ~21× as the "de-risked" multiple.
~$104 (+24%)
Base(our anchor)
Guidance roughly holds — FY26 EBITDA ~$2.1B, ~2% organic; FY27E EPS-ex-amort ~$4.75 at a ~18× multiple (in line with today). A fairly-valued deleveraging story.
~$84 (~flat)
Bear
Macro/pricing pressure stalls organic growth to ~0–1%, Food Ingredients sale disappoints or drags, debt-reduction slips. FY27E EPS ~$4.20; multiple de-rates to ~14× as the turnaround loses credibility.
~$58 (−31%)
Synthos fair value = the base case, ~$84 (roughly flat from $83.83), with the full $58–$104 span as the honest range. Our base sits just below the Street's $88.38 consensus — we credit the turnaround but see the easy re-rating as largely done, and we take the downside (impairment history, leverage, near-zero organic) more seriously than a 24-Buy sell-side skew implies. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). IFF is neither right now — it is a turnaround/repair story:
Forward growth: revenue is essentially flat. FY25 $10.89B → FY26E $10.58B → FY27E $10.55B → FY28E $10.66B → FY29E $11.96B. That's a ~1.9% CAGR headline, and the near-term line actually declines as divestitures (Food Ingredients, the Soy Crush/Concentrates/Lecithin sale) shrink the base. EPS-ex-amort CAGR FY25→FY29E is a modest ~5.8% ($4.25 → $5.32).
Acceleration (2nd derivative): none. Comparable currency-neutral growth is guided to just 1–4% for 2026, and estimates flatten thereafter. There is no inflection here — the opposite of an exponential.
Room to run: the flavors/fragrances/enzymes category is large but mature and consolidated (IFF, Givaudan, DSM-Firmenich, Symrise split it). At $21.4B market cap the "room" is not the constraint — the growth rate is. IFF is deliberately getting smaller (selling Food Ingredients), which is the right capital-allocation move but the antithesis of a room-to-run growth story.
Reinvestment runway: capex ~$0.6B/yr, ROIC ~3.6% — reinvestment returns are below the cost of capital, so growth-by-reinvestment is not the engine. Deleveraging and margin repair are.
Exponential Potential: Low (2/10). Own IFF, if at all, for a defensive dividend + a balance-sheet-repair re-rating — never for compounding or a multibagger. This honest framing is why IFF sits in Watch, not any growth sleeve.
Revenue: FY25 $10.89B, −5.2% (FY24 $11.48B; FY23 $11.48B; FY22 $12.44B). The top line has been declining for three years — partly divestitures, partly volume/FX. Q1'26 revenue $2.74B, −4% reported but +3% comparable currency-neutral (the cleaner read).
Earnings (mind the GAAP vs adjusted gap): GAAP net −$361M FY25 (dragged by a Q1'25 −$1.0B impairment; the year was profitable ex-charges). On an adjusted EPS-ex-amortization basis IFF earned ~$4.25 (FY25 est-line) and Q1'26 delivered $1.25 (vs $0.66 GAAP). The large amortization of DuPont-deal intangibles is the wedge between the two — real cash earnings are far better than the GAAP loss suggests.
Cash flow: FY25 operating CF $850M, capex −$0.6B, FCF ~$256M (depressed by working-capital and one-offs). FCF has been volatile (FY23 $936M, FY22 −$109M). Q1'26 FCF $92M, +$144M YoY — improving. FCF yield is thin (~1.2–1.9%), so the dividend (~1.9% yield, ~$0.4B/yr) consumes most of it.
Balance sheet (the crux): total debt $6.65B, cash $0.59B, net debt $6.06B, net-debt/EBITDA 2.6× — down sharply from FY24's $9.15B net debt (management repaid ~$2.9B of long-term debt in 2025 using divestiture proceeds). Deleveraging is real and is the core of the bull case. Goodwill+intangibles still $14.3B (56% of assets) — the impairment risk isn't fully behind them.
6. Valuation — priced in or room?
On adjusted earnings IFF is fairly valued, not cheap: ~25.6× trailing adjusted EPS, and on forward EPS-ex-amort ~19× FY26E → ~18× FY27E → ~16× FY29E. EV/EBITDA 13.4× and EV/Sales 2.5× are middle-of-the-road for specialty ingredients (below higher-quality peers Givaudan/DSM-Firmenich, above cyclical commodity chemicals). The FMP letter rating is B (overall 3/5), dinged on debt-to-equity (1/5) and P/E (2/5).
The bull case for the multiple is quality of earnings improving as amortization rolls off and leverage falls — a de-levered, simplified IFF arguably deserves a mid-cycle re-rate toward 20×+. The bear case is that near-zero organic growth caps the multiple regardless of balance-sheet repair: you don't pay up for a business growing 2%. Street targets (context): consensus $88.38, high $95, low $75, median $90 — our ~$84 base is slightly below consensus because we think the recovery re-rating (stock +40% off its 52-wk low) has largely happened. Not a value buy; a fairly-priced turnaround.
7. Technicals (computed from EOD price history)
Trend:up. $83.83 sits above the 50-DMA ($75.26) and 200-DMA ($70.43), 50 above 200 (golden-cross posture). MACD +1.38 (positive).
Location: literally at the 52-week high ($83.83) and +40.8% off the 52-week low ($59.55). But note the deeper scar: max drawdown from prior peak −46.5% — this is a stock that halved and is still climbing back, not one making all-time highs.
Momentum: RSI(14) 69.2 — right at the overbought line (70). Momentum is strong but stretched; this is not a low-risk entry point.
Relative strength: IFF +11.6% 12-mo vs SPY +20.6% and QQQ +30.3% — it has lagged both the market and the Nasdaq over a year, though it led over 3 months (+15.5% vs SPY +13.7%). A recent-strength, longer-term-laggard profile consistent with a turnaround bounce.
Read: technicals confirm a recovery uptrend but flash a stretched-entry warning (at 52-wk high, RSI ~70). For a Watch-rated name, that argues for patience — a pullback toward the rising 50-DMA (~$75) would be a far better risk/reward than chasing the high.
8. Moat & competitive position
IFF's moat is moderate and real but not widening: (1) formulation IP and customer lock-in — flavors/fragrances are co-developed into a customer's product and embedded in its recipe, so switching is costly and relationships are sticky (long product life, high reformulation friction); (2) scale and breadth across taste, scent, and biosciences that few can match; (3) regulatory/safety know-how in food and fragrance. The category is a stable global oligopoly — IFF, Givaudan, DSM-Firmenich, and Symrise — with rational pricing and defensive demand. The weakness: the moat protects margins and stability, not growth, and IFF is the most financially stretched of the majors after the DuPont deal.
Peer set (FMP-supplied, market cap): these are broad specialty/commodity chemicals, not pure F&F comps — Albemarle $16.0B, CEMEX $17.8B, DuPont $18.9B, Dow $20.0B, LyondellBasell $17.2B, PPG $27.9B, RPM International $14.2B, Reliance Steel $19.0B, SQM $20.8B, Westlake $9.6B. (The truer competitive comps — Givaudan, DSM-Firmenich, Symrise — trade at higher multiples reflecting cleaner balance sheets and similar-to-better growth; against those, IFF is the "cheap, levered, self-help" name.)
9. Management, capital allocation & guidance
Capital allocation: the whole strategy is portfolio simplification + deleveraging. Management repaid ~$2.9B of long-term debt in 2025 (net debt $9.15B → $6.06B) funded by divestitures, and is now running a disciplined sale process for Food Ingredients to cut leverage further. Dividend maintained (~$1.60/yr, ~1.9% yield, ~48% payout) but consumes most of FCF; buybacks are minimal. This is the right playbook for an over-levered post-merger balance sheet.
Insider activity — a genuine positive signal: director Paul Fribourg bought 260,000 + 13,500 shares (~$20M) on the open market at ~$74 in June 2026 (Form 4, 2026-06-02). Open-market purchases by a director at prices below today's — as opposed to routine RSU-vesting sales seen from other officers — is a real vote of confidence and one of the more constructive data points in this file.
Management's own guidance (half-weighted — their own book): per the Q1'26 earnings release (SEC 8-K, 2026-05-05), management reaffirmed FY2026 guidance: sales $10.5–10.8B, adjusted operating EBITDA $2.05–2.15B, comparable currency-neutral sales growth +1–4% and EBITDA growth +3–8%. They flag FX ~+1% tailwind to sales and divestitures ~−5% drag to both sales and EBITDA. CEO Fyrwald: "volume growth in all four segments, improved profitability, and strong cash flow… derisks the balance of the year." Half-weight caveat: this is management characterizing its own turnaround; the +1–4% organic guide is the honest, un-spun takeaway — modest.
10. Catalysts & what to watch
Next earnings: 2026-08-04 (Q2'26; Street EPS $1.13, revenue ~$2.68B). Key line: comparable currency-neutral organic growth (is it holding 1–4%?) and adjusted EBITDA margin trend.
Food Ingredients sale: price, timing, and use of proceeds — the single biggest swing factor. A strong price that takes net-debt/EBITDA toward ~1.5× is the bull trigger; a drawn-out or low-price process is the bear trigger.
Deleveraging trajectory: each quarter's net-debt/EBITDA print — the core of the entire thesis.
Impairment risk: with $14.3B goodwill+intangibles still on the books, watch for any further write-downs (they've recurred).
Thesis tripwires (what would change the call): organic growth slipping to ~0%; the Food Ingredients sale stalling or pricing poorly; net-debt/EBITDA rising; another material impairment; or dividend coverage breaking down.
11. Key risks
Leverage + impairment history (structural): ~$6B net debt at 2.6× EBITDA and a track record of billion-dollar goodwill write-offs (2022, 2023, 2025) mean the balance sheet is still the dominant risk. $14.3B of intangibles could impair again.
No growth engine: ~2% organic in a mature category — the valuation cannot re-rate much on a business that isn't growing.
Execution / divestiture risk: the turnaround depends on selling Food Ingredients well and continuing to cut debt; a misstep resets the story.
Valuation / stretched entry: stock at 52-wk high, RSI ~70, +40% off the low — the recovery bounce has largely played out, so downside from a stumble is asymmetric.
No expert conviction: unlike our conviction-track names, zero KB coverage — we have no independent expert breadth confirming (or refuting) the numbers, so model error is uninsured.
FX / macro: globally diversified revenue is a strength but adds currency translation noise; consumer-staples destocking can pressure volumes.
12. Verdict, position sizing & monitoring
Watch. IFF is a legitimately improving deleveraging turnaround — real debt reduction ($9.2B → $6.1B net), a defensive oligopoly business, adjusted cash earnings well above the GAAP loss, and a director putting ~$20M of his own money in at ~$74. But it is a Watch, not a Buy, for three honest reasons: (1) it trades at roughly fair value (~$84 base vs $83.83 spot; the recovery re-rating has largely happened); (2) there is no growth engine — ~2% organic and sub-cost-of-capital ROIC cap the multiple; and (3) there is zero expert coverage in the Synthos KB, so we have no conviction breadth to lean on. This is a numbers call on a fairly-priced repair story — nothing here demands ownership at the 52-week high.
Sizing: Watch-list. If an investor already owns it as a defensive/value/turnaround holding, a small ~1–2% sleeve is defensible; new money is better deployed on a pullback toward the ~$75 50-DMA than chasing RSI ~70 at the high.
Monitoring: re-underwrite on the §10 tripwires; the Food Ingredients sale and each net-debt/EBITDA print are the key updates. Formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $83.83.
Single biggest risk: the turnaround stalls — organic growth stuck near 2% while leverage and impairment risk linger — leaving a fairly-priced stock with no cushion.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — IFF has no expert coverage in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no claim_ids are cited because none exist. Fabricated conviction is structurally impossible (claim-ID reconciliation), and we do not manufacture a thesis where the panel is silent.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K earnings release dated 2026-05-05. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
GAAP vs adjusted caveat: IFF's GAAP results carry large impairment and amortization charges; we lean on adjusted operating EBITDA and adjusted EPS-ex-amortization for the earnings power read, and flag the wedge explicitly.
Management caveat: the FY26 guidance in §9 is management's own book, half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").